Sign up
Pharma Capital

Recce Pharmaceuticals attracts $1.8 million as it moves toward human clinical trials

The company’s lead candidate RECCE® 327 has been developed for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria.
bacteria
Substantial support for the capital raising

Recce Pharmaceuticals Ltd (ASX:RCE) has raised about $1.8 million from sophisticated and institutional investors via a share placement at 14 cents per share.

The funds raised will be used to strengthen Recce’s balance sheet as the company advances its new class of broad-spectrum antibiotic towards approval to start human clinical trials.

Recce has already received the Qualified Infectious Disease Product designation from the US Food and Drug Administration (US FDA) under the Generating Antibiotics Initiative Now (GAIN) Act.

In addition, the funds will be used to further pre‐clinical programs, for general working capital and repayment of $200,000 loaned by the directors.

 

Recce founder and chairman Dr Graham Melrose said: “We are encouraged by the substantial support for the capital raising, as we continue to advance RECCE® 327 in its preclinical pipeline.

“This will keep the company in a strong position to move decisively and expediently towards its first human use.”

The company’s patented lead candidate RECCE® 327 has been developed for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria – including their superbug forms.

Pre-clinical testing in laboratories and animal models, in Australia and overseas has demonstrated positive results.

Recce has a manufacturing facility in Australia and is developing clinical research partners in the USA.

The company has developed an automated process to manufacture its lead compound ahead of first-in-human clinical trials.



Register here to be notified of future RCE Company articles
View full RCE profile View Profile
View All

Related Articles

1550762209_shutterstock_291998651.jpg
Motif’s lead drug candidate is iclaprim, a next-generation antibiotic for which it was seeking US FDA approval for use in patients with acute bacterial skin and skin structure infections

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.